Fate Therapeutics (FATE) Tops Q2 EPS by 2c

August 8, 2016 5:20 PM EDT
Get Alerts FATE Hot Sheet
Trade FATE Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.02 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.02 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment